Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis
The International Journal of Biological Markers · 2025
DOI: 10.1177/03936155251335975 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biological Markers, 2025. Verfasst von Xiaoxiao Jiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Institute of Digestive Disease, Tongji Hospital, School of Medicine, Tongji University, Shanghai, P. R…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The mechanisms underlying the occurrence and progression of metabolic dysfunction-associated steatohepatitis (MASH)-related liver fibrosis remains poorly understood. This study aims to identify key transcription factors involved in the development of liver fibrosis in MASH patients, thereby providing potential targets for drug discovery.
Methods
Microarray data were retrieved from liver biopsy specimens of MASH patients exhibiting varying stages of fibrosis via the Gene Expression Omnibus database. Differentially expressed transcription factors (DETFs) were identified through the application of Weighted Gene Co-expression Network Analysis. A set of in vitro and in vivo experiments were conducted to investigate the role of MEOX1 in MASH-related fibrosis. To delineate the potential mechanisms, the transcriptomic RNA sequencing (RNA-seq), Alphafold, and PyMOL were used.
Results
A total of six DETFs (MEOX1, SOX4, LEF1, SOX9, MYC, and CBX2) were identified as being positively correlated with the progression of MASH-related fibrosis. MEOX1 was increased in mouse model of MASH diet-induced liver fibrosis and hepatic stellate cells (HSCs) stimulated by transforming growth factor-β1. Knockdown of the MEOX1 markedly suppressed the activation, proliferation, and migration of HSCs. RNA-Seq analysis identified serine protease inhibitor family E member 1 (SERPINE1) as the critical target of MEOX1 within HSCs. The protein interaction sites of MEOX1 and SERPINE1 were predicted using Alphafold and PyMOL.
Conclusion
In summary, as a pivotal transcription factor, MEOX1 activates HSCs via SERPINE1, thereby promoting liver fibrosis associated with MASH. Inhibition of the MEOX1-SERPINE1 pathway could offer a novel therapeutic avenue for treating MASH-related fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Institute of Digestive Disease, Tongji Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.
ORCID-Profile: Xiaoxiao Jiao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiao, X., Lai, L., Qian, Y., Sun, B., & Yang, W. (2025). Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis. The International Journal of Biological Markers. https://doi.org/10.1177/03936155251335975
Vancouver
Jiao X, Lai L, Qian Y, Sun B, Yang W. Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis. The International Journal of Biological Markers. 2025. doi:10.1177/03936155251335975
BibTeX
@article{Jiao2025,
author = {Jiao, Xiaoxiao and Lai, Linying and Qian, Yiting and Sun, Bo and Yang, Wenzhuo},
title = {Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis},
journal = {The International Journal of Biological Markers},
year = {2025},
doi = {10.1177/03936155251335975}
}
EUVIMED